PRA Health Sciences Inc (NASDAQ:PRAH) has earned an average rating of “Hold” from the fifteen brokerages that are covering the company, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $113.22.
Several research analysts have recently commented on PRAH shares. Leerink Swann raised AbbVie to a “buy” rating in a report on Tuesday, July 2nd. BidaskClub raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 4th. Svb Leerink reissued a “market perform” rating on shares of PRA Health Sciences in a report on Tuesday, July 2nd. ValuEngine raised Yandex from a “hold” rating to a “buy” rating in a report on Saturday, April 13th. Finally, Mizuho set a $100.00 price objective on PRA Health Sciences and gave the stock a “hold” rating in a report on Friday, May 3rd.
PRAH stock traded up $0.31 during mid-day trading on Friday, reaching $97.80. 467,183 shares of the company traded hands, compared to its average volume of 534,532. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $6.40 billion, a P/E ratio of 24.89, a P/E/G ratio of 1.32 and a beta of 1.12. PRA Health Sciences has a 52-week low of $82.12 and a 52-week high of $121.98. The company has a fifty day moving average price of $94.73.
Large investors have recently added to or reduced their stakes in the stock. Motco lifted its position in PRA Health Sciences by 937.0% in the 1st quarter. Motco now owns 280 shares of the medical research company’s stock worth $31,000 after buying an additional 253 shares during the last quarter. Financial Gravity Wealth Inc. bought a new stake in PRA Health Sciences in the 1st quarter worth approximately $53,000. Manchester Capital Management LLC bought a new stake in PRA Health Sciences in the 1st quarter worth approximately $57,000. CENTRAL TRUST Co lifted its position in PRA Health Sciences by 28.2% in the 1st quarter. CENTRAL TRUST Co now owns 842 shares of the medical research company’s stock worth $93,000 after buying an additional 185 shares during the last quarter. Finally, Carroll Financial Associates Inc. lifted its position in PRA Health Sciences by 7.6% in the 1st quarter. Carroll Financial Associates Inc. now owns 1,517 shares of the medical research company’s stock worth $167,000 after buying an additional 107 shares during the last quarter. Institutional investors own 99.42% of the company’s stock.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.